Latest news with #QDEL
Yahoo
3 days ago
- Business
- Yahoo
QDEL Q1 Earnings Call: Cost Savings and Tariff Mitigation Anchor 2025 Outlook
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) met Wall Street's revenue expectations in Q1 CY2025, but sales fell by 2.6% year on year to $692.8 million. The company's outlook for the full year was close to analysts' estimates with revenue guided to $2.71 billion at the midpoint. Its non-GAAP profit of $0.74 per share was 24.9% above analysts' consensus estimates. Is now the time to buy QDEL? Find out in our full research report (it's free). Revenue: $692.8 million vs analyst estimates of $689.8 million (2.6% year-on-year decline, in line) Adjusted EPS: $0.74 vs analyst estimates of $0.59 (24.9% beat) Adjusted EBITDA: $159.8 million vs analyst estimates of $149.4 million (23.1% margin, 7% beat) The company reconfirmed its revenue guidance for the full year of $2.71 billion at the midpoint Management reiterated its full-year Adjusted EPS guidance of $2.32 at the midpoint EBITDA guidance for the full year is $595 million at the midpoint, in line with analyst expectations Operating Margin: 4.7%, up from -247% in the same quarter last year Market Capitalization: $2.09 billion QuidelOrtho's first quarter results were shaped by growth in its core laboratories segment, stable immunohematology performance, and a robust flu testing season, offset by lower COVID-related and donor screening revenues. CEO Brian Blaser highlighted that the labs business, now over half of total revenue, delivered 7% year-over-year growth, while immunohematology grew 4%. Blaser credited the company's ongoing cost reduction initiatives—including staffing cuts and procurement efficiencies—for a 450 basis point improvement in adjusted EBITDA margin. The company also benefited from increased sales of its COVID-flu combination tests, which Blaser described as showing 'very stable performance,' helping mitigate the broader decline in COVID-only testing volumes. Management characterized the quarter as further evidence that its 2024 operational changes are positively impacting profitability and business stability. Looking ahead, QuidelOrtho's management sees its narrowed set of strategic priorities—expanding platform content, margin improvement, and targeted commercial execution—as key drivers for 2025. Blaser emphasized the company's plans to fully offset anticipated tariff headwinds, noting, 'We believe the incremental actions we are taking are sufficient to fully offset the tariff impacts as they stand today.' The company expects recurring revenues from consumables to underpin stability, supported by a diversified manufacturing footprint. CFO Joe Busky added that visibility into labs and immunohematology growth in China supports a mid- to high-single-digit outlook for that market, assuming the tariff environment remains unchanged. Management remains focused on delivering cost savings and maintaining profitability targets, while monitoring for potential shifts in COVID and flu testing demand. Management attributed the quarter's performance to solid growth in non-COVID segments, benefits from prior cost-reduction actions, and strong execution in the labs and flu testing businesses. Labs business momentum: Core laboratories led growth, with consistent demand in clinical chemistry and immunoassay testing, representing over half of Q1 revenue. Immunohematology stability: The immunohematology segment maintained its global leadership with steady 4% growth, particularly benefiting from strength in the Europe, Middle East, and Africa region. Flu and combo testing resilience: Sales of flu tests and the COVID-flu combination test remained strong, offsetting the expected decline in pure COVID testing. The durability of the combo product contributed to recurring revenue streams. Cost savings initiatives: Operational changes—including staff reductions, procurement efficiencies, and expense controls—were credited with expanding non-GAAP margins and reducing operating costs. Management expects further incremental savings in 2025. Tariff mitigation efforts: The company outlined a multi-pronged strategy to counter expected $30–40 million tariff headwinds. Actions include re-sourcing materials, adjusting supply chains, selective pricing, and ongoing inventory repositioning. Management stated these steps are expected to fully neutralize tariff effects on financial results. QuidelOrtho's outlook for 2025 is anchored by recurring revenue growth in core segments, ongoing cost control, and strategies to manage external headwinds such as tariffs. Recurring consumables revenue: Management highlighted that over 90% of sales stem from consumables, providing a stable revenue foundation less susceptible to one-time instrument sales volatility. The company expects this model to drive consistent growth, especially in labs and immunohematology. Cost discipline and savings: The company is on track to realize the remainder of its $100 million annualized cost savings program, with additional procurement and cash flow initiatives expected to deliver a further $30–50 million in savings during 2025. These efforts are intended to support margin expansion even as the company faces external cost pressures. Tariff and macro environment management: Expected tariff headwinds are being addressed through supply chain adjustments, selective price increases, and cost reductions. Management expressed confidence that these measures will allow QuidelOrtho to maintain its guidance even if the tariff situation evolves, but noted that ongoing monitoring is required due to the dynamic nature of global trade policy. In the coming quarters, the StockStory team will be watching (1) the pace at which cost savings and procurement initiatives translate into sustained margin gains, (2) the impact of tariff mitigation actions on both supply chain flexibility and pricing power, and (3) any changes in demand for respiratory testing—particularly the COVID-flu combination test. Progress on Savanna respiratory panel submission and broader product pipeline developments will also serve as key signposts for tracking execution. QuidelOrtho currently trades at a forward P/E ratio of 12.1×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Yahoo
15-05-2025
- Business
- Yahoo
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time. San Diego, CA-based QuidelOrtho Corporation (earlier known as Quidel Corporation) is a key player in the provision of in-vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine. The company sells its products directly to end users and distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent-care clinics, leading universities, retail clinics, pharmacies and wellness screening centers. QDEL boasts a Growth Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 27% year-over-year for 2025, while Wall Street anticipates its top line to improve by 2.3%. Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.01 to $2.35 per share. QDEL boasts an average earnings surprise of 70.8%. Looking at cash flow, QuidelOrtho is expected to report cash flow growth of 226% this year; QDEL has generated cash flow growth of 68.8% over the past three to five years. QDEL should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QuidelOrtho Corporation (QDEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Why QuidelOrtho Corporation (QDEL) Went Up On Thursday
We recently published a list of In this article, we are going to take a look at where QuidelOrtho Corporation (NASDAQ:QDEL) stands against other Thursday's top-performing stocks. The stock market extended its winning streak on Thursday as investors cheered President Donald Trump's trade deal framework between the United States and the United Kingdom. Among Wall Street's major indices, the tech-heavy Nasdaq rallied the most, up 1.07 percent, followed by the Dow Jones, up 0.62 percent, and the S&P 500, gaining 0.58 percent. According to Trump, the Oval Office outlined a trade deal framework. While a 10-percent baseline tariff will remain for imported goods from the UK, it could be the low end of deals with future countries. 'The final details are being written up,' Trump said. 'In the coming weeks, we'll have it all very conclusive.' Beyond the major indices, 10 firms stood out, booking double-digit gains amid a flurry of fresh developments such as optimistic revenue guidance and impressive earnings performance, among others. In this article, let us explore Thursday's 10 top-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A scientist observing the results of a molecular diagnostic test. QuidelOrtho saw its share price expand by 41.04 percent on Thursday to close at $36.46 apiece after almost wiping out its net losses during the first quarter of the year. In a statement on Thursday, QuidelOrtho Corporation (NASDAQ:QDEL) said it narrowed its net loss by 99 percent to $12.7 million from $1.7 billion recorded in the same period last year, despite revenues dipping by 2.56 percent to $692.8 million from $711 million year-on-year. The lag in revenues can be owed to the flat performance of its non-respiratory revenue, which was at $573 million. Meanwhile, respiratory revenues ended at $120 million, marking an 11 percent growth year-on-year. Looking ahead, QuidelOrtho Corporation (NASDAQ:QDEL) expects revenues to settle anywhere between $2.6 billion and $2.81 billion, with adjusted EBITDA ranging from $575 million to $615 million. For the full year, the company also targets to book between $30 million and $40 million in tariff impact, which it targets to mitigate through cost actions. Overall, QDEL ranks 3rd on our list of Thursday's top-performing stocks. While we acknowledge the potential of QDEL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than QDEL but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
09-05-2025
- Business
- Yahoo
Why QuidelOrtho Corporation (QDEL) Went Up On Thursday
We recently published a list of In this article, we are going to take a look at where QuidelOrtho Corporation (NASDAQ:QDEL) stands against other Thursday's top-performing stocks. The stock market extended its winning streak on Thursday as investors cheered President Donald Trump's trade deal framework between the United States and the United Kingdom. Among Wall Street's major indices, the tech-heavy Nasdaq rallied the most, up 1.07 percent, followed by the Dow Jones, up 0.62 percent, and the S&P 500, gaining 0.58 percent. According to Trump, the Oval Office outlined a trade deal framework. While a 10-percent baseline tariff will remain for imported goods from the UK, it could be the low end of deals with future countries. 'The final details are being written up,' Trump said. 'In the coming weeks, we'll have it all very conclusive.' Beyond the major indices, 10 firms stood out, booking double-digit gains amid a flurry of fresh developments such as optimistic revenue guidance and impressive earnings performance, among others. In this article, let us explore Thursday's 10 top-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A scientist observing the results of a molecular diagnostic test. QuidelOrtho saw its share price expand by 41.04 percent on Thursday to close at $36.46 apiece after almost wiping out its net losses during the first quarter of the year. In a statement on Thursday, QuidelOrtho Corporation (NASDAQ:QDEL) said it narrowed its net loss by 99 percent to $12.7 million from $1.7 billion recorded in the same period last year, despite revenues dipping by 2.56 percent to $692.8 million from $711 million year-on-year. The lag in revenues can be owed to the flat performance of its non-respiratory revenue, which was at $573 million. Meanwhile, respiratory revenues ended at $120 million, marking an 11 percent growth year-on-year. Looking ahead, QuidelOrtho Corporation (NASDAQ:QDEL) expects revenues to settle anywhere between $2.6 billion and $2.81 billion, with adjusted EBITDA ranging from $575 million to $615 million. For the full year, the company also targets to book between $30 million and $40 million in tariff impact, which it targets to mitigate through cost actions. Overall, QDEL ranks 3rd on our list of Thursday's top-performing stocks. While we acknowledge the potential of QDEL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than QDEL but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
QuidelOrtho (NASDAQ:QDEL) Reports Q1 In Line With Expectations, Stock Soars
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) met Wall Street's revenue expectations in Q1 CY2025, but sales fell by 2.6% year on year to $692.8 million. The company's outlook for the full year was close to analysts' estimates with revenue guided to $2.71 billion at the midpoint. Its non-GAAP profit of $0.74 per share was 25% above analysts' consensus estimates. Is now the time to buy QuidelOrtho? Find out in our full research report. QuidelOrtho (QDEL) Q1 CY2025 Highlights: Revenue: $692.8 million vs analyst estimates of $689.8 million (2.6% year-on-year decline, in line) Adjusted EPS: $0.74 vs analyst estimates of $0.59 (25% beat) Adjusted EBITDA: $159.8 million vs analyst estimates of $149.4 million (23.1% margin, 7% beat) The company reconfirmed its revenue guidance for the full year of $2.71 billion at the midpoint Management reiterated its full-year Adjusted EPS guidance of $2.32 at the midpoint EBITDA guidance for the full year is $595 million at the midpoint, in line with analyst expectations Operating Margin: 4.7%, up from -247% in the same quarter last year Constant Currency Revenue fell 1.1% year on year (-15.5% in the same quarter last year) Market Capitalization: $1.75 billion 'We delivered solid first quarter performance driven by growth in our Labs business and the strength of our recurring revenue business model,' said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. Company Overview Born from the 2022 merger of Quidel and Ortho Clinical Diagnostics, QuidelOrtho (NASDAQ:QDEL) develops and manufactures diagnostic testing solutions for healthcare providers, from rapid point-of-care tests to complex laboratory instruments and systems. Sales Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, QuidelOrtho's sales grew at an excellent 23.3% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers. QuidelOrtho Quarterly Revenue We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. QuidelOrtho's recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 5.7% over the last two years. QuidelOrtho Year-On-Year Revenue Growth We can better understand the company's sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 8.9% year-on-year declines. Because this number is lower than its normal revenue growth, we can see that foreign exchange rates have boosted QuidelOrtho's performance.
